Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria

Trial Profile

An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs AK 002 (Primary) ; Antihistamines
  • Indications Urticaria
  • Focus Therapeutic Use
  • Acronyms CURSIG
  • Sponsors Allakos
  • Most Recent Events

    • 11 Feb 2019 Data from Chronic Urticaria study cohorts presented in the Allakos media release.
    • 29 Jan 2019 According to an Allakos media release, top-line results for the remaining urticaria cohort, patients with chronic spontaneous urticaria who failed to respond to Xolair, are expected later in the first quarter of 2019. More detailed results from the study will be presented at an upcoming medical conference.
    • 29 Jan 2019 Results published in an Allakos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top